NMRC and WRAIR will conduct studies to submit an IND application in decompression sickness.

The Naval Medical Research Center (NMRC) and the Walter Reed Army Institute of Research (WRAIR) inked a deal with Oxygen Biotherapeutics to use the firm’s perfluorocarbon (PFC) therapeutic oxygen carrier for decompression sickness (DCS) and arterial gas embolism (AGE).

Under the terms of the limited-purpose CRADA, the firm will provide information that NMRC and WRAIR will use for preparation, writing, and submission of an IND application for Oxycyte in decompression sickness.

Oxygen Biotherapeutics will retain ownership of and IP related to the product. If the research is successful and the Navy gets FDA approval to use Oxycyte, the company will have an exclusive option to license the rights to these new indications.

NMRC and the company’s primary research partner, Virginia Commonwealth University Reanimation Shock Center, have developed a $3.8 million research program dedicated to determining the efficacy of PFCs for treating DCS and AGE. The program’s ultimate goal is to make a PFC preparation like Oxycyte available for the treatment of DCS and AGE by the fiscal year 2012.

Related News
Vical Commissioned for $1.3M to Produce Dengue Vaccine and Adjuvant for NMRC’s Evaluation (Nov. 6, 2008)
MVI Awards Additional Funding to GenVec and NMRC for Malaria Vaccine Program (May 1, 2007)
Arbor Vita and WRAIR Ally to Advance Therapy for Traumatic Brain Injury (Sep. 8, 2008)
WRAIR and Maas BiolAB Manufacture Neuroprotective Agent (Dec. 15, 2006)

Previous articleSpecial Report: Patentability of Genetic Sequences Limited
Next articleKuDOS Acquires Oncology Candidates from Cancer Research UK